{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:50:06Z","timestamp":1760385006346},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T00:00:00Z","timestamp":1259020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Drug\u2013drug interactions (DDIs) may have a profound impact on the individual drug response, for instance by reducing the clearance of involved drugs and thereby causing adverse drug reactions at supratherapeutic drug exposure.<\/jats:p><jats:p>\u2022\u2003In specific cases, such a risk with specific drug combinations is stated in the drug label, including specific recommendations on the choice of drug and\/or dose.<\/jats:p><jats:p>\u2022\u2003Less frequently, DDIs that reduce the drug effectiveness may have been recognized as well.<\/jats:p><jats:p>\u2022\u2003The clinical adherence to these recommendations is today unknown.<\/jats:p><jats:p> <jats:bold>WHAT THIS ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The results from this study on specific drug combinations related to cytochrome P450\u2010dependent drug metabolism indicate that Swedish doctors avoid prescribing strong inhibitors of drug metabolism together with drugs at risk of accumulation and exposure\u2010dependent adverse drug reactions.<\/jats:p><jats:p>\u2022\u2003However, \u2018silent\u2019 DDIs that impact on effectiveness appear to be neglected, pointing out an area for continued medical education of drug prescribers about such DDIs.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> The study aimed to investigate the clinical adherence to drug label recommendations on important drug\u2013drug interactions (DDIs). Dispensing data on drug combinations involving selective serotonin reuptake inhibitor (SSRI) antidepressants could help to identify areas for intensified medical education.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> This was a retrospective, cross\u2010sectional analysis of individual dispensing data regarding all individuals \u226515 years old in Sweden. The study analysed the prescribing and dispensing of CYP2D6 drugs (metoprolol, donepezil, galantamine, codeine, tamoxifen) together with CYP2D6\u2010blocking SSRIs (paroxetine\/fluoxetine) or SSRIs without significant CYP2D6 inhibition (citalopram\/escitalopram\/sertraline), and the related prescribing of CYP2D6\u2010independent comparator drugs (atenolol, rivastigmine, propoxyphene, anastrozole). Odds were calculated between each CYP2D6 drug and the corresponding comparator drug in patients on fluoxetine\/paroxetine and citalopram\/escitalopram\/sertraline, respectively. The odds ratio (OR) was calculated by dividing the obtained odds in patients on fluoxetine\/paroxetine by the corresponding odds in patients on citalopram\/escitalopram\/sertraline.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Compared with patients that were dispensed citalopram\/escitalopram\/sertraline, patients dispensed fluoxetine\/paroxetine had lower prescribing rates of metoprolol (adjusted OR 0.80; 95% confidence interval 0.76, 0.85), donepezil (0.65; 0.49, 0.86) and galantamine (0.58; 0.41, 0.81). In contrast, the use of prodrugs codeine (compared woth propoxyphene) or tamoxifen (compared with anastrozole) was similar among patients on fluoxetine\/paroxetine and citalopram\/escitalopram\/sertraline (adjusted OR 1.03; 0.94, 1.12 and 1.29; 0.96, 1.73, respectively).<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Clinically important DDIs that are associated with impaired bioactivation of prodrugs might be more easily neglected in clinical practice compared with DDIs that cause drug accumulation and symptomatic adverse drug reactions.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03598.x","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T11:05:38Z","timestamp":1259060738000},"page":"411-417","source":"Crossref","is-referenced-by-count":19,"title":["Nationwide drug\u2010dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6\u2010dependent drug interactions"],"prefix":"10.1111","volume":"69","author":[{"given":"Buster","family":"Mannheimer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Von Bahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12266"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1351"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032424"},{"key":"e_1_2_7_5_2","unstructured":"FDIUDom.Drug Interaction Table. Available athttp:\/\/medicine.iupui.edu\/flockkhart\/table.htm(last accessed 23 October 2009)."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0877-2"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.017"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.02040.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00080-3"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199700321-00003"},{"key":"e_1_2_7_11_2","unstructured":"FASS.The Swedish Catalogue of Approved Medical Products.2008."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018960"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.2.119"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104788"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498257809060956"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.5.553"},{"key":"e_1_2_7_18_2","volume-title":"Pharmaca Fennica","author":"Aricept","year":"2004"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317130-00002"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.212"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050200"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280101"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9428-0"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3266"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250400008371"},{"key":"e_1_2_7_26_2","unstructured":"WHO.Guidelines for ATC classification and DDD assignment.2008. Available athttp:\/\/www.whocc.no(last accessed 23 October 2009)."},{"key":"e_1_2_7_27_2","unstructured":"Statistiska Centralbyr\u00e5n (SCB).Statistics Sweden.2009. Available athttp:\/\/www.scb.se\/Pages\/List____250612.aspx(last accessed 23 October 2009)."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.01329.x"},{"key":"e_1_2_7_29_2","unstructured":"Swedish Breast Cancer.Group guidelines.2009. Available athttp:\/\/www.swebcg.se\/Files\/Docs\/Nationella_riktlinjer091027.pdf(last accessed 13 December 2009)."},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90062-X"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1006"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2003.00193.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050329"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00040-1"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200701000-00002"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0547-x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0612-5"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00434.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzn038"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03598.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03598.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:37:03Z","timestamp":1697409423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03598.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03598.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03598.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}